NO20065782L - Modulering av WRN-mediert telomer-initiert celle signalisering - Google Patents

Modulering av WRN-mediert telomer-initiert celle signalisering

Info

Publication number
NO20065782L
NO20065782L NO20065782A NO20065782A NO20065782L NO 20065782 L NO20065782 L NO 20065782L NO 20065782 A NO20065782 A NO 20065782A NO 20065782 A NO20065782 A NO 20065782A NO 20065782 L NO20065782 L NO 20065782L
Authority
NO
Norway
Prior art keywords
wrn
modulation
cell signaling
initiated cell
mediated telomere
Prior art date
Application number
NO20065782A
Other languages
English (en)
Norwegian (no)
Inventor
Barbara A Gilchrest
Mark S Eller
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Publication of NO20065782L publication Critical patent/NO20065782L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
NO20065782A 2004-05-19 2006-12-13 Modulering av WRN-mediert telomer-initiert celle signalisering NO20065782L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57262504P 2004-05-19 2004-05-19
PCT/US2005/017553 WO2005113764A2 (en) 2004-05-19 2005-05-19 Modulation of wrn-mediated telomere-initiated cell signaling

Publications (1)

Publication Number Publication Date
NO20065782L true NO20065782L (no) 2006-12-18

Family

ID=34982215

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065782A NO20065782L (no) 2004-05-19 2006-12-13 Modulering av WRN-mediert telomer-initiert celle signalisering

Country Status (16)

Country Link
US (1) US20080221052A1 (de)
EP (2) EP1761629A2 (de)
JP (1) JP2007537758A (de)
KR (1) KR20070030219A (de)
CN (2) CN1965076B (de)
AU (1) AU2005245932A1 (de)
BR (1) BRPI0511142A (de)
CA (1) CA2566859C (de)
HK (1) HK1104062A1 (de)
IL (1) IL179199A (de)
MX (1) MXPA06013263A (de)
NO (1) NO20065782L (de)
NZ (1) NZ551323A (de)
RU (1) RU2006144817A (de)
TR (2) TR200606490A2 (de)
WO (1) WO2005113764A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086941A1 (en) * 2008-10-01 2010-04-08 Adami Guy R Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
RU2550267C2 (ru) * 2012-12-12 2015-05-10 Елена Андреевна Чирясова Способ воздействия на пролиферативный статус клеток с помощью специфических нуклеотидных последовательностей g-цепи теломерной днк человека
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
JP2021527713A (ja) * 2018-06-15 2021-10-14 イデアヤ、バイオサイエンシズ、インコーポレイテッドＩｄｅａｙａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 増殖性細胞を抑制する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US6090620A (en) * 1995-12-29 2000-07-18 University Of Washington Genes and gene products related to Werner's syndrome
US6228583B1 (en) * 1997-08-04 2001-05-08 Massachusetts Institute Of Technology Assays for compounds which extend life span
EP1274410A2 (de) * 2000-03-31 2003-01-15 Trustees Of Boston University Verwendung von lokal aplizierten dna-fragmenten
SE0200929D0 (sv) 2002-03-26 2002-03-26 Alstom Switzerland Ltd An apparatus and method for suspending a stator core of an electric generator
JP2007525162A (ja) 2003-04-11 2007-09-06 トラスティーズ オブ ボストン ユニバーシティ テロメアにより開始される細胞シグナル伝達の調節

Also Published As

Publication number Publication date
CN101869575A (zh) 2010-10-27
JP2007537758A (ja) 2007-12-27
IL179199A (en) 2010-12-30
MXPA06013263A (es) 2007-08-14
EP1761629A2 (de) 2007-03-14
CA2566859A1 (en) 2005-12-01
KR20070030219A (ko) 2007-03-15
NZ551323A (en) 2010-03-26
HK1104062A1 (en) 2008-01-04
CN1965076B (zh) 2011-01-26
TR200606490A2 (tr) 2008-05-21
BRPI0511142A (pt) 2007-12-04
WO2005113764A2 (en) 2005-12-01
EP2434009A1 (de) 2012-03-28
RU2006144817A (ru) 2008-06-27
TR200606490T1 (tr) 2007-01-22
US20080221052A1 (en) 2008-09-11
CN1965076A (zh) 2007-05-16
AU2005245932A1 (en) 2005-12-01
CA2566859C (en) 2011-07-19
IL179199A0 (en) 2007-03-08
WO2005113764A3 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE530637T1 (de) Kulturmedium mit kinasehemmern und verwendung
NO20065782L (no) Modulering av WRN-mediert telomer-initiert celle signalisering
ATE402709T1 (de) Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
NO20084627L (no) Pyrrolo- og tiazolpyridinforbindelser og fremgangsmater for anvendelse derav
MX2021003559A (es) Inhibidores de vap-1.
SG170041A1 (en) Methods for cancer therapy and stem cell modulation
DE50313372D1 (de) INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE
PL1846424T3 (pl) Inhibitory proteasomów oraz metody ich zastosowania
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
AR057800A1 (es) Compuestos ppar activos
TW200613731A (en) Flow modulation devices
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
IL173722A0 (en) Proteasome inhibitors and methods of using the same
WO2019178267A3 (en) Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
SG166770A1 (en) Use of adipose tissue-derived stromal stem cells in treating fistula
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
WO2010065850A3 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
AU2014213514B2 (en) Biological Materials And Uses Thereof
MX364002B (es) Compuestos y composiciones activadoras de enzima.
WO2020069335A3 (en) Inhibitors of vap-1